Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARCUS W LEE

Allopathic & Osteopathic Physicians Family Medicine

NPI
1457364077
CMS profile
20974
Location
TULLAHOMA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$20.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $20.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARCUS W LEE

NPI 1457364077 · CMS profile ID 20974

Allopathic & Osteopathic Physicians / Family Medicine

TULLAHOMA, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457364077?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARCUS W LEE, NPI 1457364077, CMS profile ID 20974. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457364077?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARCUS W LEE, NPI 1457364077, CMS profile ID 20974. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457364077?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARCUS W LEE, NPI 1457364077, CMS profile ID 20974, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1457364077?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $20.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $20.0006/03/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833593793 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,069.95 90
PY2021 $20.00 1
PY2024 $351.93 19
PY2025 $413.66 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $41,224.32 19
PY2021 Principal investigator $508,494.07 158
PY2020 Principal investigator $652,209.70 156
PY2019 Principal investigator $293,637.72 176

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

158 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $501.76 12/29/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832568663
Principal investigator 1 PFIZER INC. $921.60 12/28/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832568653
Principal investigator 1 PFIZER INC. $3,266.56 12/24/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832568645
Principal investigator 1 Novo Nordisk AS $1,482.84 12/22/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811120741
Principal investigator 1 Novo Nordisk AS $4,332.42 12/22/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616713
Principal investigator 1 PFIZER INC. $3,300.48 12/22/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832569997
Principal investigator 1 ABBVIE INC. $1,745.30 12/09/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792486197
Principal investigator 1 CHIESI USA, INC. $10,500.00 12/08/2021 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
Not supplied No dispute reported 06/30/2026 849319989
Principal investigator 1 PFIZER INC. $1,756.80 12/07/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832570007
Principal investigator 1 Novo Nordisk AS $4,172.40 11/24/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811806853
Principal investigator 1 PFIZER INC. $22,434.56 11/23/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832634737
Principal investigator 1 Novo Nordisk AS $25.06 11/22/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746437
Principal investigator 1 PFIZER INC. $2,467.84 11/18/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832698859
Principal investigator 1 Novo Nordisk AS $23.06 11/10/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870217
Principal investigator 1 PFIZER INC. $2,836.48 11/10/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832837715
Principal investigator 1 ABBVIE INC. $1,807.85 11/09/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792481791
Principal investigator 1 Novo Nordisk AS $23.06 11/04/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432955
Principal investigator 1 PFIZER INC. $1,331.20 10/30/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832798911
Principal investigator 1 Novo Nordisk AS $3,284.10 10/29/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811456759
Principal investigator 1 Novo Nordisk AS $1,627.56 10/27/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616703
Principal investigator 1 PFIZER INC. $1,751.04 10/27/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832794567
Principal investigator 1 PFIZER INC. $501.76 10/16/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832836873
Principal investigator 1 Novo Nordisk AS $23.06 10/14/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432945
Principal investigator 1 PFIZER INC. $1,331.20 10/09/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832693031
Principal investigator 1 Novo Nordisk AS $23.70 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746233
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746243
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746253
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746263
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746271
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746281
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746291
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746331
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746339
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746349
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746359
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746369
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746379
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746389
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746398
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746407
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746417
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746427
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869707
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869721
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869735
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869749
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869763
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869777
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869805
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869813
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869827
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869841
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870095
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870109
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870123
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870137
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870149
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870163
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870177
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870191
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810870205
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432775
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432785
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432817
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432827
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432837
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432849
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432857
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432867
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432877
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432887
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432897
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432907
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432917
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432925
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432935
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616595
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616605
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616615
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616625
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616633
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616643
Principal investigator 1 Novo Nordisk AS $6.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616653
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616663
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616673
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616683
Principal investigator 1 Novo Nordisk AS $13.00 10/08/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616693
Principal investigator 1 PFIZER INC. $3,399.68 10/05/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832783085
Principal investigator 1 PFIZER INC. $5,683.20 09/25/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832702795
Principal investigator 1 PFIZER INC. $5,130.24 09/21/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832795325
Principal investigator 1 PFIZER INC. $17,838.08 09/15/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832634553
Principal investigator 1 PFIZER INC. $5,857.28 09/14/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832890177
Principal investigator 1 PFIZER INC. $7,925.76 09/08/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832789323
Principal investigator 1 PFIZER INC. $1,105.92 08/31/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832849691
Principal investigator 1 PFIZER INC. $4,919.04 08/27/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832634563
Principal investigator 1 Novo Nordisk AS $358.02 08/25/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869693
Principal investigator 1 PFIZER INC. $3,502.08 08/24/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832844333
Principal investigator 1 PFIZER INC. $65,235.20 08/21/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832634747
Principal investigator 1 Novo Nordisk AS $23.06 08/20/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746223
Principal investigator 1 PFIZER INC. $460.80 08/14/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832846279
Principal investigator 1 Novo Nordisk AS $23.06 08/11/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432767
Principal investigator 1 PFIZER INC. $460.80 08/07/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832698275
Principal investigator 1 Novo Nordisk AS $23.06 08/05/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869665
Principal investigator 1 PFIZER INC. $3,915.12 08/03/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832814307
Principal investigator 1 ABBVIE INC. $1,119.33 07/29/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792469395
Principal investigator 1 Novo Nordisk AS $716.04 07/28/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869679
Principal investigator 1 Novo Nordisk AS $637.74 07/28/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811456749
Principal investigator 1 PFIZER INC. $2,917.12 07/24/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832888375
Principal investigator 1 PFIZER INC. $8,500.00 07/21/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 832634573
Principal investigator 1 Novo Nordisk AS $23.06 07/15/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811616585
Principal investigator 1 PFIZER INC. $921.60 07/14/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832708285
Principal investigator 1 PFIZER INC. $1,843.20 07/07/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832725147
Principal investigator 1 Novo Nordisk AS $1,077.30 06/28/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810747045
Principal investigator 1 Novo Nordisk AS $1,232.28 06/28/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811456779
Principal investigator 1 PFIZER INC. $501.76 06/23/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832899555
Principal investigator 1 PFIZER INC. $524.80 06/16/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832862065
Principal investigator 1 PFIZER INC. $2,288.64 06/09/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832755001
Principal investigator 1 Novo Nordisk AS $2,371.14 05/28/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811120781
Principal investigator 1 ABBVIE INC. $1,927.57 05/27/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792460185
Principal investigator 1 PFIZER INC. $2,030.08 05/26/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832890183
Principal investigator 1 PFIZER INC. $10,567.68 05/22/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832836307
Principal investigator 1 Novo Nordisk AS $23.06 05/21/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746212
Principal investigator 1 PFIZER INC. $3,914.24 05/15/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832879337
Principal investigator 1 Novo Nordisk AS $23.06 05/12/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432757
Principal investigator 1 PFIZER INC. $3,312.64 05/05/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832698821
Principal investigator 1 PFIZER INC. $26,571.04 05/01/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832711541
Principal investigator 1 Novo Nordisk AS $1,113.30 04/26/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811120767
Principal investigator 1 PFIZER INC. $2,664.96 04/24/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832874741
Principal investigator 1 PFIZER INC. $19,384.18 04/17/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832789437
Principal investigator 1 Novo Nordisk AS $23.06 04/16/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746321
Principal investigator 1 PFIZER INC. $6,453.76 04/07/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832767801
Principal investigator 1 PFIZER INC. $14,420.48 04/03/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832890167
Principal investigator 1 ABBVIE INC. $741.77 03/30/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792436517
Principal investigator 1 Novo Nordisk AS $358.02 03/29/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746987
Principal investigator 1 PFIZER INC. $14,494.72 03/27/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832899563
Principal investigator 1 Novo Nordisk AS $250.00 03/24/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811120755
Principal investigator 1 Novo Nordisk AS $23.06 03/24/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432807
Principal investigator 1 Novo Nordisk AS $1,999.08 03/24/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811456769
Principal investigator 1 PFIZER INC. $14,877.16 03/20/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832844343
Principal investigator 1 PFIZER INC. $4,723.20 03/10/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832740119
Principal investigator 1 PFIZER INC. $25,569.28 03/06/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832861085
Principal investigator 1 ABBVIE INC. $741.77 03/02/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792427437
Principal investigator 1 PFIZER INC. $6,755.84 02/27/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832773631
Principal investigator 1 Novo Nordisk AS $250.00 02/24/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811617081
Principal investigator 1 Novo Nordisk AS $719.28 02/24/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811617091
Principal investigator 1 Novo Nordisk AS $2,077.38 02/22/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 811840497
Principal investigator 1 PFIZER INC. $11,906.56 02/20/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832899519
Principal investigator 1 Novo Nordisk AS $23.06 02/19/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810869791
Principal investigator 1 Novo Nordisk AS $23.06 02/11/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746311
Principal investigator 1 PFIZER INC. $23,398.40 02/10/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832737823
Principal investigator 1 PFIZER INC. $35,555.84 02/06/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832839873
Principal investigator 1 Novo Nordisk AS $41.06 02/05/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 810746301
Principal investigator 1 ABBVIE INC. $6,352.78 01/28/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH LLC
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study No dispute reported 06/30/2026 792413885
Principal investigator 1 PFIZER INC. $12,480.00 01/27/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832806618
Principal investigator 1 Novo Nordisk AS $1,879.74 01/26/2021 Non-covered Recipient Entity
TRINITY CLINICAL RESEARCH
EX9924-4473 No dispute reported 06/30/2026 811432797
Principal investigator 1 PFIZER INC. $7,308.80 01/23/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832844665
Principal investigator 1 PFIZER INC. $19,814.40 01/13/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832757265
Principal investigator 1 PFIZER INC. $1,049.60 01/08/2021 Non-covered Recipient Entity
Roberta AdamsTrinity Clinical Research LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 832822893